ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2021. The put-call ratio across all filers is 8.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $718,811 | -21.0% | 20,163 | +2.2% | 0.01% | -14.3% |
| Q2 2023 | $909,776 | +17.6% | 19,722 | +2.2% | 0.01% | 0.0% |
| Q1 2023 | $773,810 | -11.0% | 19,297 | +2.8% | 0.01% | -12.5% |
| Q4 2022 | $869,799 | +16.3% | 18,774 | +4.0% | 0.01% | 0.0% |
| Q3 2022 | $748,000 | -29.8% | 18,053 | +1.1% | 0.01% | -20.0% |
| Q2 2022 | $1,066,000 | -16.1% | 17,863 | +2.1% | 0.01% | 0.0% |
| Q1 2022 | $1,271,000 | -12.9% | 17,504 | +0.9% | 0.01% | -9.1% |
| Q4 2021 | $1,459,000 | -7.4% | 17,345 | -0.7% | 0.01% | -15.4% |
| Q3 2021 | $1,575,000 | -4.5% | 17,463 | +1.0% | 0.01% | 0.0% |
| Q2 2021 | $1,649,000 | -20.8% | 17,289 | -5.5% | 0.01% | -27.8% |
| Q1 2021 | $2,083,000 | -9.9% | 18,295 | +9.6% | 0.02% | -14.3% |
| Q4 2020 | $2,311,000 | +64.1% | 16,693 | -2.5% | 0.02% | +50.0% |
| Q3 2020 | $1,408,000 | +45.0% | 17,128 | +38.0% | 0.01% | 0.0% |
| Q2 2020 | $971,000 | +69.8% | 12,413 | -3.7% | 0.01% | +40.0% |
| Q1 2020 | $572,000 | – | 12,884 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |